PULSE-trial: Summarising the Clinical Outcomes and Benefits of iVAC 2L ® in Clinical Practice: An Expert Discussion with Prof Nicolas van Mieghem

  • Published:  25 October 2021
  • Likes: 

    Heart Icon

    1

Up Next

PULSE-trial: Summarising the Clinical Outcomes and Benefits of iVAC 2L ® in Clinical Practice: An Expert Discussion with Prof Nicolas van Mieghem

  • Published:  25 October 2021
  • Likes: 

    Heart Icon

    1

Average (ratings)
No ratings
Your rating
Overview

In this video series, Professor Nicolas van Mieghem will discuss the benefits of iVAC 2L ® in clinical practice and will share the learnings and key outcomes from the Pulse Trial, and the effect of next generation pulsatile mechanical circulatory support (MCS).

 

This video is supported by PulseCath in collaboration with their co-sponsors: CardiRad, Sanomed, LeviBio, Thomy F.E., Sonimed and Dot Medical.

 

Click Here for Publication: Effect of next generation pulsatile mechanical circulatory support on cardiac mechanics - The PULSE trial

 

This video series is sponsored by:

Key Learning Objectives

  • Learn when to use the short term percutaneous ventricular assist device (pVAD), iVAC 2L ® in clinical practice
  • Understand the differences between pulsatile and continuous flow
  • Understand the technology behind the device
  • Gain a better understanding of how the iVAC 2L ® is more efficient
  • Learn how to identify the right patient (HR PCI)
  • Learn when to use iVAC 2L ® vs Impella
  • Further understanding of large bore access management

Target Audience

  • Interventional Cardiologists
  • Cardiac Surgeons
  • Cardiac Nurses
  • Cath Lab Nurses
  • ICU Doctors
  • Perfusionists
  • Cath Lab Technicians

More from this programme

Part 1

Full Programme - PULSE-trial: Summarising the Clinical Outcomes and Benefits of iVAC 2L ® in Clinical Practice: An Expert Discussion with Prof Nicolas van Mieghem

Part 3

iVAC 2L ® - pVAD procedure

Part 5

iVAC 2L experience from CINRE hospital – Bratislava - Slovakia

Part 7

Procedure IVAC 2L in high risk PCI University Hospital of Bellvitge, Barcelona, (Spanish)

Dr Joan Antoni Gomez-Hospital (University Hospital of Bellvitge, Barcelona, ES) shares his experience on the iVAC 2L and the practical issues. 

Part 8

iVAC 2L experience from University Hospital of Bellvitge, Barcelona, ES

Faculty Biographies

Nicolas M Van Mieghem

Nicolas M Van Mieghem

Full Professor of Interventional Cardiology

Prof Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002. Prof Van Mieghem believes that great cardiologist genuinely cares for their patients. He names Gary Roubin, Dr Manu Malbrain and Professor Patrick Serruys among his mentors. 

 

Academic History

Prof. Nicolas M. Van Mieghem completed his medical training at the Catholic University of Leuven (Belgium), where he earned both his medical degree and his specialist degree in cardiology. During his time in Leuven, he developed a strong interest in cardiovascular medicine, particularly in the emerging field of minimally invasive cardiac interventions. After finishing his core medical and cardiology training, he pursued multiple advanced…

View full profile